Radiofrequency Ablation Versus Hemithyroidectomy of Small Thyroid Cancers

Sponsor
University of Aarhus
Study ID
NCT06796348
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Thyroid Cancer

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiofrequency ablation alone — PROCEDURE
    RFA of a cancer in the thyroid gland.
  • Surgery — PROCEDURE
    Hemithyroidectomy of the thyroid lobe with cancer

Study Details

This is a multicenter randomized controlled trial including patients with small (\<2 cm) suspected or confirmed thyroid cancers. Patients are included after informed consent and randomized to one of two treatments. One treatment is a standard henithyroidectomy and the second treatment is radiofrequency ablation (RFA) of the specific tumor. The investigators will evaluate initial outcome of the allocated treatment, thyroid hormonal function, oncologic safety, quality of life, and treatment costs in a follow-up period of five years after treatment. The overall aim of the study is to improve patient's health by reducing the number of operations on small thyroid cancers. In patients with these small tumors, the long-term adverse outcome may be higher than possible benefits from the operation. For participants undergoing surgical treatment with HT, the investigators will measure final histology and both beneficial and adverse outcome from the operation. For participants undergoing RFA, the investigators expect to reduce the need for thyroid hormonal substitutions, reduce the surgical adverse outcomes, reduce treatment costs and increase QoL without a reduction in oncologic safety and outcome.

Key Dates

First listed
Jan 28, 2025
Start date
Mar 1, 2025
Status verified
Dec 2024
Primary completion
Feb 28, 2028
Completion
Apr 1, 2028

Study Design

Enrollment
88 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Surgery of thyroid cancer
  • Experimental: RFA of thyroid cancer

Primary Outcome Measure

Uncomplicated initial treatment (yes/no) [ Time Frame: One month after randomization. ]

Central Contacts

Related Studies